29th-31st January 2018

Paris, France

Day One
Wednesday 25th January, 2017

Day Two
Thursday 26th January, 2017

08.00
Registration & Networking

08.50
Chair’s Opening Remarks

Seizing the Microbiome: Can We Sort the Hype from the Hope?

09.00
Perspectives on a Microbiome-Based Industry: How Far Are We From Science to Products?

Synopsis

  • What are the most successful microbiome trends with clear therapeutic potential?
  • Exploring the current financial perspective in an emerging microbiome based industry
  • Why the microbiome industry is set to be bigger than the biotechnology bubble

09.30
Studying Microbiome-Host Interactions to Translate Microbiome Drugs into the Clinic

  • David Cook Executive Vice President of Research & Development and, Chief Scientific Officer Seres Therapeutics

Synopsis

  • Review of approaches to mine microbiological and functional information from human
  • clinical trials
  • Using mechanistic data and pharmacological models to design and test microbiome drugs
  • Discussion of regulatory and CMC considerations for translating microbiome drugs into clinical trials

10.00
EB8010 – A Novel Therapeutic Approach Targeting the Microbiome in Patients With Crohn’s Disease.

Synopsis

  • Emerging evidence suggests that the microbiome plays an important role in triggering an abnormal mucosal immune response in patients with Crohn’s Disease.
  • Independent studies have demonstrated an imbalance of the microbiome with a significant
  • increase of E. coli with invasive properties, termed adherent-invasive E. coli (AIEC). These
  • AIEC bacteria attach to the gut wall of susceptible patients via the fimbrial adhesion protein
  • FimH, and subsequently trigger inflammation by invading and proliferating within the gut wall.
  • EB8018 is a novel first-in-class molecule targeted to disarm AIEC bacteria by blocking the FimH adhesion and reducing the subsequent production of inflammatory cytokines in the gut wall.

10.30
Microbial Adaptations of the Microbiome

Synopsis

  • Delivering concepts and tools that target microbial integration in the microbiome
  • Understanding how persistence probabilities in the microbiome can be learned from longitudinal studies
  • Using metatranscriptomics to show microbiome response to new microorganisms

11.00
Morning Refreshments and Speed Networking

Translating the Microbiome: Moving From Observational Science to Evidence-Based Medicine

12.00
Where the Microbiome Will Matter for the Pharmaceutical Industry and Why

Synopsis

  • Positioning in academics and a microbiome start-up, in the largest medical centre in the world, provides a unique perspective on translational microbiome research
  • Clear evolution of project design: from retrospective to prospective, from associations to causality
  • Critical mass is building for the phase of pharma-based microbiome initiatives

12.30
Human-Microbe Interactions: A Drug Discovery Perspective

Synopsis

  • A deeper dialogue is occurring between infectious and chronic disease disciplines
  • The microbiome opens new therapeutic paradigms for many chronic diseases
  • The host-pathogen interactome offers new ways for treating infectious diseases
  • Using examples from GSK research the translational science of the microbiome and interactome will be discussed

13.00
Development of Pathogen-Specific Antimicrobials to Restore Balance to the Human Microbiome

Synopsis

  • Selective antimicrobial peptides remove pathogens and spare the healthy microbiome
  • Clinical data support proof of concept for reengineering the oral microbiome
  • Clinical experience enables product development innovation
  • Advancing to the clinic with targeted antimicrobials for the gut microbiome

13.30
Lunch and Networking

Predicting the Microbiome: Improved Preclinical Models for Drug Discovery

14.30
A Systems Biology Approach to Measuring Human-Microbiome Interactions

Synopsis

  • How to use computational platforms to elucidate disease causalities
  • Mathematical modelling can be leveraged to understand basic mechanisms in human metabolism
  • What are the key disease type mathematical modelling can look to improve?
  • Can mathematical models be used to design modulation of the gut microbiome to treat diseases?

15.00
Using Germ-free Mouse Models to Modulate Liver Disease Development

Synopsis

  • Outlining the key research that validates the influence on the liver by the gut microbiota
  • Human gut-microbiota transplants into germ-free suggests that targeting the gut microbiota could be a new therapeutic approach for liver disease management
  • Gut microbiota transplants to germ-free mice can be used in the context of other diseases

Build Winning Partnerships to Achieve Holistic Microbiome Success

15.30
Panel Discussion: What Role Will Academic-Industrial Partnerships Play in Leveraging the Potential Success of Microbiome Therapeutics?

Synopsis

  • How can we combine Academic knowledge with industrial processes to elucidate
  • fundamental mechanisms?
  • Outlining the current global successes with establishing microbiome partnerships
  • In a multi-functional team of experts, where do we place the key responsibilities?
  • How to build a win-win research project in partnership to industrialize microbiome
  • applications?

16.00
Afternoon Refreshments and Networking

16.30
Seizing the Opportunity: Breakout Roundtables

Synopsis

  1. Food versus Pharma- Where will the Microbiome have the Maximum Success?
  • With successful applications in both nutrition and drug development, which approach will be more successful in short and long term?
  • Regulation
  • Project Management
  • Switching from a medical food mindset to a pharmaceutical mind-set
  • Why is there less money invested in the nutrition route?

Jean-Luc Treillou, CEO, Laboratories Nutrition et Cardiometabolism

 

  1. Where the Microbiome will Matter for the Pharmaceutical Industry and Why?
  • How to apply a pharmaceutical model to an undefined scientific phenomenon?
  • Changing your research approaches, clinical design and business models to develop a successful pharma-biotech relationship
  • How can big pharma resources be best utilised to accelerate the microbiome R&D?

John Hambor, Director of Research Beyond Borders, Boehringer Ingelheim

17.15
Chair’s Closing Remarks

17.25
End of Conference Day 1